C

Cencora

Distributes medicines and supports patient care

Territory Manager

Full-TimeUpdated on 10/23/2026
$62.4k - $97.9k
Junior, Mid
Bachelor's
Seattle, WA, USA
In Person
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor’s degree or an equivalent combination of experience and education is required.
  • A valid driver’s license and a good driving record are mandatory.
  • Excellent interpersonal, presentation, and organizational skills and a proven ability to sell are necessary.
  • Speak effectively in individual or group situations, recognize and present information to others, select appropriate communication methods, and deliver information with positive impact.
  • Be customer-oriented, responsive to customer needs and priorities, establish effective working relationships, and identify and act on customer needs.
  • Understand the company’s objectives and structure, work effectively within the organization, and build internal linkages and networks.
  • Know customers and key competitors in the market territory, understand customer segments, build customer relationships, and identify marketplace opportunities.
  • Define quality service based on customer needs and profitability, align actions accordingly, respond to internal and external customers, and resolve problems effectively.
  • Demonstrate proficiency in explaining, selling, and administering products, and refer customers to appropriate organizational resources.
  • Keep informed of technological advances affecting the industry, identify useful technological applications, and apply internal technology effectively.
  • Communicate openly, honestly, and respectfully; check message clarity; understand the effect of communication style and adapt to others’ communication preferences and needs.
Responsibilities
  • Call on target, current, and prospective customers to generate sales, improve market share, and increase income for MWI.
  • Use the computer as a sales aid and competently use MWI email, MWI promotions in Outlook, and the MWI Territory Manager website.
  • Understand the needs of veterinarians and clinics and select products and services to satisfy those needs.
  • Establish appropriate relationships with veterinarians and clinics.
  • Review and use sales analysis and top supplier reports in pre-call and post-call planning.
  • Prepare and maintain a written call cycle consistent with territory changes, and share call-cycle information with the inside sales representative and Regional Manager. Call-cycle information includes account number, name, location, and day of the week.
  • Stay current on the full line of products and services offered by MWI.
  • Demonstrate competency in MWI sales programs, promotions, and products.
  • Establish account profiles for customers within the territory and respond to communications from customers, MWI team members, and manufacturer representatives.
  • Detail or demonstrate new products and promotions for customers.
  • Submit reporting on time.
  • Meet sales goals and budget numbers by territory and manufacturer.
  • Advise customers on business matters, including inventory management, equipment, and products.
  • Act as the point person for customers on nearly all dealings with the company and work with MWI inside personnel to resolve customer issues.
  • Maintain the vehicle in a professional manner.
  • Work closely with key vendors and Product Specialists.
  • Maintain adequate support materials and detail aids in the automobile.
  • Comply with other requests from MWI Regional Managers and leadership.
  • Participate in conference calls and meetings as requested.
Desired Qualifications
  • One to three years of relevant industry or sales experience, preferably in animal health.

About the company

Cencora buys and distributes medicines for pharmacies, hospitals and physician practices, while helping drug manufacturers bring treatments to patients. Its businesses combine wholesale supply networks with specialty distribution for complex therapies and services that support prescribing and patient access. Customers order medicines through its distribution systems, and its teams manage sourcing, storage and delivery alongside pharmacy operations and manufacturer support. It earns revenue from pharmaceutical sales and fees for logistics and healthcare services. The parent company was formed in 2001 through the merger that created AmerisourceBergen, adopted the Cencora name in 2023, and is headquartered in Conshohocken, Pennsylvania.

Company Size

10,001+

Company Stage

IPO

Headquarters

Conshohocken, Pennsylvania

Founded

2001

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pharmacy contracts deepen customer ties: Cencora negotiates insurer agreements and handles administrative work through its managed-care networks.
  • Eligible US staff gain retirement support: Cencora counts student-loan payments toward its employer match, up to 4% of pay.
  • Drug demand expands sales: Cencora reported 5.1% quarterly revenue growth in August 2026, led by higher US volumes.

What critics are saying

  • Customer dependence concentrates risk: Walgreens and Boots supplied 25% of Cencora's fiscal 2025 revenue, reported in November 2025.
  • Legal liabilities tie up cash: Cencora's November 2025 filing recorded $4.3 billion in opioid settlements, payable over 13 years.
  • Warehouse work is physical: Cencora's day-shift associate listing requires repeated lifting up to 50 pounds and overtime availability.

What makes Cencora unique

  • Independent pharmacies get a shared brand: Cencora's Good Neighbor Pharmacy franchise supports their merchandising and store identity.
  • Specialty shipments use reusable packaging: Cencora's World Courier Cocoon containers combine passive temperature control with live location monitoring.
  • Medicines arrive ready for bedside checks: Cencora's American Health Packaging sells barcoded unit doses that support hospital scanning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Paid Parental Leave
  • Adoption Assistance
  • Infertility Coverage
  • Family Planning Benefits
  • Behavioral Health Solutions
  • Professional Development Budget
  • Training Programs

Company News

Financial News
Oct 21st, 2026
Cencora to buy American Oncology Network in $2.4bn deal

Cencora agrees to buy American Oncology Network for $2.4bn enterprise value, but a stockholder rollover means it may land only 75% of the company.

Yahoo Finance
Oct 16th, 2026
Cencora stock: $332.8B revenue, 14.4% EPS growth and 50.2% ROIC

Cencora, the pharmaceutical distributor formerly known as AmerisourceBergen, has risen 6% to $341.69 per share over the past six months. The S&P 500 gained 9.7% in the same period. The New York Stock Exchange-listed company (NYSE:COR) connects drug manufacturers with healthcare providers and offers logistics, data analytics, and consulting services. It rebranded in 2023. Its revenue reached $332.8 billion over the past 12 months, giving it scale and bargaining power with suppliers. That matters in a low-margin, volume-driven business. Earnings per share grew at a 14.4% compound annual rate over five years, outpacing 10.2% annualised revenue growth. Its five-year average return on invested capital was 50.2%. The shares trade at 17.4 times forward earnings.

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.